Tech Company Financing Transactions
Blaze Bioscience Funding Round
Blaze Bioscience closed a $9 million Series B financing round on 12/3/2013. Backers included private investors.
Transaction Overview
Company Name
Announced On
12/3/2013
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series B
Investors
Proceeds Purpose
The funds will be used to support the clinical development of Blaze's first Tumor PaintTM product candidate, BLZ-100, which is designed to assist surgeons in surgical excision of solid tumors by illuminating cancer cells intra-operatively in real time and at high resolution. A Phase 1 clinical trial of BLZ-100 will be initiated shortly. In addition, the company will use proceeds to support development of Optide drug candidates as part of the collaboration and option agreement entered into with Fred Hutchinson Cancer Research Center in June of this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
530 Fairview Ave. North 1400
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Website
Email Address
Overview
Blaze has taken on this inspiration as we meet the challenge of moving quickly to advance our first Tumor Paint product candidate, BLZ-100, through clinical trials and onto the market where we believe it will eventually help millions of cancer patients.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/2/2013: Fluential venture capital transaction
Next: 12/3/2013: XLumena venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs